JPJohn William Pickering

John William Pickering

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John William Pickering has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Troponin Thresholds for Risk Stratification of Chest Pain Patients Presenting to the Emergency Department: Alternatives to the 99th Percentile

    by John W Pickering, Dimitrios Doudesis, Lori B Daniels, W Frank Peacock, Laura R Joyce, A Mark Richards, Richard Troughton, Chris J Pemberton, Martin P Than

    Background: Two methods are used to determine cardiac troponin (cTn) thresholds for high-risk stratification for myocardial infarction (MI), namely the assay’s healthy population 99th percentiles and a threshold that has a positive predictive value (PPV) of about 70%. We hypothesized that these methods may produce inconsistent prediction of MI risk. Methods: We compared the positive likelihood ratio (LR+), sensitivity, and specificity at 99th percentiles and published high-risk thresholds for a high-sensitivity (hs) cTnI (Abbott) and cTnT (Roche) assay. We simulated the high-risk threshold derivation methodology that derives thresholds with 70% PPV as a function of prevalence and sample size. We derived and validated thresholds based on LR+ = 20 and specificity = 95%. Results: In 2584 patients there was an almost 2-fold difference in LR+ between males and females at the sex-specific 99th percentiles, and a 2- to 3-fold difference between assays. Thresholds giving 70% PPV were much higher in lower-prevalence cohorts for both assays, being 3- to 10-fold lower at 5% than 20% prevalence. Thresholds derived using a LR+ or specificity had similar performance in a validation cohort between sexes but had a 2-fold difference in LR+ in a validation cohort between assays. Conclusions: In patients presenting to the emergency department with possible MI, sex-specific 99th percentile thresholds convey lower risk of MI for females than males. Risks also differed between assays. Risk thresholds derived using the PPV vary considerably with the prevalence and size of cohort. Thresholds derived with specificity or positive likelihood ratio had more consistent risk-prediction.

  • Open Access

    Protocol for an individual patient data meta-analysis for the assessment of risk factors affecting the development and outcome of functional and structural acute kidney injury after cardiac surgery: the METARIS CS-AKI study

    by Annemarie Albert, Frederike Vogel, Linda Krause, Louisa Blume, Prasad Devarajan, John Pickering, Salvatore Di Somma, Mina Hur, Hanah Kim, Chul Min Park, et al.

    Introduction In addition to serum creatinine (SCr), a kidney functional biomarker, structural damage biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) may improve identification of patients at risk of adverse outcomes after cardiac surgery. Previous meta-analyses have relied on study-level data, functional acute kidney injury (AKI) definitions and heterogeneous NGAL cut-off concentrations, limiting comparability and clinical interpretation. Methods and analysis We will conduct an individual patient data (IPD) meta-analysis of prospective studies investigating NGAL in adult patients undergoing cardiac surgery. Authors of eligible studies will be contacted to provide IPD according to a prespecified data request form. Primary outcomes will be the AKI incidence, initiation of renal replacement therapy and in-hospital mortality after surgery. SCr and NGAL will be analysed both as continuous predictors and using study-specific as well as harmonised IPD-derived cut-off values to characterise AKI phenotypes and predictors of adverse outcomes enabling the quantification of risk across the full spectrum of NGAL and SCr concentrations. Exploratory analyses using mixed-effects logistic regression models will investigate patient-level characteristics that may modify clinical risk for the development of AKI and related adverse outcomes. The study results will be reported in accordance with the Preferred Reporting Items for a Systematic Review and Meta-Analysis of Individual Participant Data. The findings may improve biomarker-guided risk stratification after cardiac surgery. Ethics and dissemination Ethics approval was obtained for all included studies by the respective ethics committees or institutional review boards. This meta-analysis is exempt from additional ethical approval because it uses anonymised data from previously published studies with informed consent already obtained. Findings will be disseminated through national and international conferences and may be published in separate peer-reviewed articles according to the scope of the analyses. PROSPERO registration number CRD420261336943.

  • Open Access

    ICare-FASTER (Improving Care by Faster Risk Stratification Through Use of High-Sensitivity Point-of-Care Troponin in Patients Presenting With Possible Acute Coronary Syndrome in the Emergency Department): A Stepped-Wedge Cluster-Randomized Trial

    by Martin Than, John W. Pickering, Laura R. Joyce, Vanessa Buchan, Christopher M. Florkowski, Nicholas L. Mills, Laura Hamill, Jason Prystowsky, Simon Harger, Mary Reed, et al.

    BACKGROUND: Point-of-care high-sensitivity cTn (cardiac troponin; hs-cTn) testing has the potential to expedite decision-making and reduce emergency department (ED) length of stay for patients presenting with possible myocardial infarction by ensuring that results are consistently available when sought by clinicians. We assessed the real-life effectiveness and safety of implementing point-of-care hs-cTn testing in the ED. METHODS: We conducted a pragmatic, stepped-wedge cluster-randomized trial. The control arm was usual care with an accelerated diagnostic pathway using a single-sample rule-out step with a central laboratory hs-cTn assay. The intervention arm used the same pathway with a point-of-care hs-cTnI assay. The primary effectiveness outcome was ED length of stay assessed using a generalized linear mixed model. The safety outcome was myocardial infarction or cardiac death within 30 days. RESULTS: Six sites participated, with 59 980 ED presentations (44 747 individuals; mean 61±19 years of age; 49.5% female) from February 2023 through January 2025; 31 392 presentations were during the intervention arm. After adjustment for covariates associated with length of stay, the intervention reduced length of stay by 13% (95% CI, 9%–16%; P P =0.54). CONCLUSIONS: Implementation of whole-blood hs-cTnI testing at the point of care into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing. REGISTRATION: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12619001189112.

  • Open Access

    Analytical Verification of a Point-of-Care High-Sensitivity Troponin I Assay

    by John W Pickering, Vanessa Buchan, Megan Rodney, Tamsin Attenburrow, Laura R Joyce, Martin Than, Christopher M Florkowski

    Background: To provide independent evidence of the analytical performance of the i-STAT high-sensitivity troponin I assay using the i-STAT Alinity system, we assessed imprecision, hemolysis interference, and concordance with laboratory assays. Methods: Nine whole-blood samples with concentrations from below the limit of quantitation to approximately 10 times the upper reference limit were analyzed 20 times in succession. Four samples across a similar range were used to assess hemolysis interference induced by repeated aspiration through a 25-gauge needle. Concordance with 4 laboratory comparison assays was assessed with 200 samples by Pearson correlation and κ statistics at the upper reference limit (URL) and compared to concordance between the laboratory assays. Results: CVs were <10% across the range of 10 to 20 ng/L, below the universal URL. There were small changes with hemolysis but within acceptable limits (±3 ng/L below 10 ng/L and ±30% above 10 ng/L). Correlation coefficients with high-sensitivity troponin I laboratory assays ranged from 0.96 to 0.99, and performance across the URL ranged from a κ of 0.67 to 0.89, similar to results between laboratory assays (correlation range, 0.87–0.98; κ at the URL range, 0.71–0.88). Conclusions: Imprecision met manufacturer claims and was consistent with a high-sensitivity assay. There was no significant hemolysis interference. Concordance with comparison laboratory assays was similar to that between laboratory assays. The results support performance characteristics previously reported by the manufacturer, and the assay and analyzer offer acceptable performance for intended clinical use. Australian New Zealand Clinical Trials Registry number: ACTRN12625000710426.

  • Open Access

    Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomized trial

    by Martin Than, John W. Pickering, Laura R Joyce, Vanessa Buchan, Christopher M Florkowski, Nicholas L. Mills, Laura Hamill, Jason Prystowsky, Simon Harger, Mary Reed, et al.

    BACKGROUND: Point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) testing has the potential to expedite decision-making and reduce emergency department (ED) length of stay for patients presenting with possible myocardial infarction (MI) by ensuring that results are consistently available when looked for by clinicians. We assessed the real-life effectiveness and safety of implementing POC hs-cTn testing in the ED. METHODS: We conducted a pragmatic, stepped-wedge cluster randomized trial. The control arm was usual care with an accelerated diagnostic pathway utilizing a single-sample rule-out step with a central laboratory hs-cTn assay. The intervention arm used the same pathway with a POC hs-cTnI. The primary effectiveness outcome was ED length of stay assessed using a generalized linear mixed model, and the safety outcome was 30-day MI or cardiac death. RESULTS: Six sites participated with 59,980 ED presentations (44,747 individuals, 61±19 years, 49.5% female) from February 2023 to January 2025, in which 31,392 presentations were during the intervention arm. After adjustment for co-variates associated with length of stay, the intervention reduced length of stay by 13% (95% confidence intervals [CI], 9 to 16%. P<0.001), corresponding to a reduction of 47 minutes (95%CI, 33 to 61 minutes) from a mean length of stay in the control arm of 376 minutes. The 30-day MI or cardiac death rate was similar in the control and intervention arms (0.39% and 0.39% respectively, P=0.54). CONCLUSIONS: Implementation of whole-blood hs-cTnI testing at the POC into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing. (Australia New Zealand Clinical Trials Registry ACTRN12619001189112) Clinical Perspective: What is new?: Point-of-care troponin assays with good precision have become available and received regulatory approval as high-sensitivity assays. A pragmatic stepped-wedge cluster randomized trial implementing the validated Siemens VTLi high-sensitivity point-of-care assay into 6 emergency departments investigating ∼60,000 patients, was conducted to ascertain if the rapid turnaround time reduced lengths of stay. Introduction of the VTLi high-sensitivity point-of-care assay into clinical pathways reduced emergency department lengths of stay by an average 13% (47 minutes) without compromising safety. What are the clinical implications?: Early decision-making using a point-of-care high-sensitivity troponin assay within a structured clinical pathway was safe. Faster turnaround means troponin results are consistently available when clinicians first seek them. This can facilitate earlier decisions and reduce patient length of stay.

  • Open Access

    Analytical Verification of a Point-of-Care High-Sensitivity Troponin I Assay

    by John W Pickering, Stephen du Toit, Stacey Cheer, Vanessa Buchan, Rory Miller, Laura R Joyce, Martin Than, Christopher M Florkowski

    Background: The QuidelOrtho TriageTrue® point-of-care (POC) high-sensitivity troponin I (hs-TnI) assay has been previously validated. We aimed to independently verify the assay’s analytical performance and concordance with other assays and to verify secondary POC devices. Methods: Intra-assay precision: 5 whole blood samples spanning the measuring interval were analyzed up to 20 times in succession. Inter-analyzer and inter-lot precision studies were also carried out and a precision curve generated. Hemolysis was assessed by spiking 8 samples with concentrations from 2 to 320 ng/L with hemolysate. Concordance between >200 TriageTrue samples and one other hs-TnI POC and 4 laboratory analyzers was assessed by Pearson correlation and kappa statistics at the limit of quantitation and upper reference limit. Paired measurements from 9 samples between a primary verified device and 8 secondary devices were compared against prespecified difference limits. Results: Intra-assay precision CVs were 25% and 12.2% at mean concentrations of 2.4 ng/L and 8.5 ng, respectively, and ranged from 2.8% to 15.9% at higher concentrations >10 ng/L. There was minimal interference by hemolysis up to 10 g/L, which exceeded the manufacturer’s claim of 1.96 g/L. Correlation coefficients were 0.89 to 0.99 with other assays with the exception of the Roche hs-TnT assay, where it was 0.79. These were similar to the laboratory assays. Of 116 comparisons with 8 secondary analyzers, all fell within acceptable limits. Conclusions: The TriageTrue assay performed as reported in the package insert. The assay characteristics offer acceptable performance for use within the intended medical settings.


  • Point‐of‐Care High‐Sensitivity Troponin Use in an ESC ‐Type Pathway for Assessment of Possible Acute Myocardial Infarction in the Emergency Department

    by Logan Fann, Laura R. Joyce, John W. Pickering, Andrew Munro, Nick Fisher, Martin Than

    This prospective observational study aimed to assess the diagnostic utility of point‐of‐care (POC) high‐sensitivity troponin (hs‐cTn) within an ED chest pain pathway. Patients had paired laboratory hs‐cTnT and POC hs‐cTnI on arrival. Clinical care utilised the hs‐cTnT result. Allocation to risk classes was compared between hs‐cTnT and POC hs‐cTnI. AMI was adjudicated blinded to the POC result. Of 184 patients, 14 (7.6%) had AMI. Twenty‐one (11.4%) had AMI ruled out by hs‐cTnT and 59 (32.1%) by POC, both with 100% sensitivity. The POC test returned invalid results in 17 patients (8.5%). A POC hs‐cTnI assay within a clinical pathway may effectively risk stratify for AMI.


  • Open Access

    Potential impact of a point-of-care high-sensitivity cardiac troponin assay on emergency department length of stay and patient disposition: findings from a cardiac emergency department

    by Robert Meek, Zhong Xian Lu, Udara Dilrukshi Senarathne, Sean Tan, Louise Cullen, John W Pickering, Martin Paul Than, Georgina Hayden, Adam Damianopoulos, Claire Charteris, et al.


  • Open Access

    Improving Emergency Department Prescribing of Anticoagulation for Atrial Fibrillation Through an Iterative Quality Improvement Process

    by Finn Brokenshire, Kaleb Addy, John W. Pickering, Ibrahim Al‐Busaidi, Martin Than, Richard Troughton, Laura R. Joyce

    Objective: To assess the impact of two iterations of an emergency department (ED) atrial fibrillation (AF) pathway on anticoagulant prescribing.Methods: Two quality improvement projects gave targeted anticoagulation guidance for AF. Anticoagulation prescription rates and related adverse events were monitored across four cohorts over 9 years (2014–2023).Results: A total of 1425 patients were included. The proportion of patients discharged from ED on anticoagulation increased from 45% to 83%. Sixty‐day thromboembolic events, bleeding events and all‐cause mortality were unchanged.Conclusions: Targeted anticoagulation guidance within an AF pathway improved adherence without raising adverse events.